169 related articles for article (PubMed ID: 18494550)
21. The fate of hypoxic (pimonidazole-labelled) cells in human cervix tumours undergoing chemo-radiotherapy.
Durand RE; Aquino-Parsons C
Radiother Oncol; 2006 Aug; 80(2):138-42. PubMed ID: 16916562
[TBL] [Abstract][Full Text] [Related]
22. Hypoxia in human intraperitoneal and extremity sarcomas.
Evans SM; Hahn SM; Magarelli DP; Zhang PJ; Jenkins WT; Fraker DL; Hsi RA; McKenna WG; Koch CJ
Int J Radiat Oncol Biol Phys; 2001 Feb; 49(2):587-96. PubMed ID: 11173159
[TBL] [Abstract][Full Text] [Related]
23. Biodistribution of the nitroimidazole EF5 (2-[2-nitro-1H-imidazol-1-yl]-N-(2,2,3,3,3-pentafluoropropyl) acetamide) in mice bearing subcutaneous EMT6 tumors.
Laughlin KM; Evans SM; Jenkins WT; Tracy M; Chan CY; Lord EM; Koch CJ
J Pharmacol Exp Ther; 1996 May; 277(2):1049-57. PubMed ID: 8627516
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] in human patients: implications for hypoxia measurements in vivo by 2-nitroimidazoles.
Koch CJ; Hahn SM; Rockwell K; Covey JM; McKenna WG; Evans SM
Cancer Chemother Pharmacol; 2001 Sep; 48(3):177-87. PubMed ID: 11592338
[TBL] [Abstract][Full Text] [Related]
25. Does heterogeneity of pimonidazole labelling correspond to the heterogeneity of radiation-response of FaDu human squamous cell carcinoma?
Yaromina A; Hölscher T; Eicheler W; Rosner A; Krause M; Hessel F; Petersen C; Thames HD; Baumann M; Zips D
Radiother Oncol; 2005 Aug; 76(2):206-12. PubMed ID: 16024121
[TBL] [Abstract][Full Text] [Related]
26. Comparisons among pimonidazole binding, oxygen electrode measurements, and radiation response in C3H mouse tumors.
Raleigh JA; Chou SC; Arteel GE; Horsman MR
Radiat Res; 1999 May; 151(5):580-9. PubMed ID: 10319731
[TBL] [Abstract][Full Text] [Related]
27. Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole 18F-EF5.
Ziemer LS; Evans SM; Kachur AV; Shuman AL; Cardi CA; Jenkins WT; Karp JS; Alavi A; Dolbier WR; Koch CJ
Eur J Nucl Med Mol Imaging; 2003 Feb; 30(2):259-66. PubMed ID: 12552344
[TBL] [Abstract][Full Text] [Related]
28. Detection of hypoxia by [18F]EF5 in atherosclerotic plaques in mice.
Silvola JM; Saraste A; Forsback S; Laine VJ; Saukko P; Heinonen SE; Ylä-Herttuala S; Roivainen A; Knuuti J
Arterioscler Thromb Vasc Biol; 2011 May; 31(5):1011-5. PubMed ID: 21372297
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the Hypoxia PET Tracer (18)F-EF5 to Immunohistochemical Marker EF5 in 3 Different Human Tumor Xenograft Models.
Chitneni SK; Bida GT; Zalutsky MR; Dewhirst MW
J Nucl Med; 2014 Jul; 55(7):1192-7. PubMed ID: 24854792
[TBL] [Abstract][Full Text] [Related]
30. Detection of tumour hypoxia: comparison between EF5 adducts and [18F]EF3 uptake on an individual mouse tumour basis.
Mahy P; De Bast M; Gillart J; Labar D; Grégoire V
Eur J Nucl Med Mol Imaging; 2006 May; 33(5):553-6. PubMed ID: 16523307
[TBL] [Abstract][Full Text] [Related]
31. The 2-nitroimidazole EF5 is a biomarker for oxidoreductases that activate the bioreductive prodrug CEN-209 under hypoxia.
Wang J; Foehrenbacher A; Su J; Patel R; Hay MP; Hicks KO; Wilson WR
Clin Cancer Res; 2012 Mar; 18(6):1684-95. PubMed ID: 22167409
[TBL] [Abstract][Full Text] [Related]
32. Measurements of hypoxia using pimonidazole and polarographic oxygen-sensitive electrodes in human cervix carcinomas.
Nordsmark M; Loncaster J; Aquino-Parsons C; Chou SC; Ladekarl M; Havsteen H; Lindegaard JC; Davidson SE; Varia M; West C; Hunter R; Overgaard J; Raleigh JA
Radiother Oncol; 2003 Apr; 67(1):35-44. PubMed ID: 12758238
[TBL] [Abstract][Full Text] [Related]
33. In situ oxygen utilization in the rat intervertebral disc.
Lee DC; Adams CS; Albert TJ; Shapiro IM; Evans SM; Koch CJ
J Anat; 2007 Mar; 210(3):294-303. PubMed ID: 17331178
[TBL] [Abstract][Full Text] [Related]
34. Tumor-dependent kinetics of partial pressure of oxygen fluctuations during air and oxygen breathing.
Cárdenas-Navia LI; Yu D; Braun RD; Brizel DM; Secomb TW; Dewhirst MW
Cancer Res; 2004 Sep; 64(17):6010-7. PubMed ID: 15342381
[TBL] [Abstract][Full Text] [Related]
35. The use of pimonidazole to characterise hypoxia in the internal environment of an in vivo tissue engineering chamber.
Hofer SO; Mitchell GM; Penington AJ; Morrison WA; RomeoMeeuw R; Keramidaris E; Palmer J; Knight KR
Br J Plast Surg; 2005 Dec; 58(8):1104-14. PubMed ID: 16043148
[TBL] [Abstract][Full Text] [Related]
36. Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding.
Evans SM; Judy KD; Dunphy I; Jenkins WT; Nelson PT; Collins R; Wileyto EP; Jenkins K; Hahn SM; Stevens CW; Judkins AR; Phillips P; Geoerger B; Koch CJ
Cancer Res; 2004 Mar; 64(5):1886-92. PubMed ID: 14996753
[TBL] [Abstract][Full Text] [Related]
37. Reductive metabolism of the hypoxia marker pimonidazole is regulated by oxygen tension independent of the pyridine nucleotide redox state.
Arteel GE; Thurman RG; Raleigh JA
Eur J Biochem; 1998 May; 253(3):743-50. PubMed ID: 9654074
[TBL] [Abstract][Full Text] [Related]
38. Patterns and levels of hypoxia in head and neck squamous cell carcinomas and their relationship to patient outcome.
Evans SM; Du KL; Chalian AA; Mick R; Zhang PJ; Hahn SM; Quon H; Lustig R; Weinstein GS; Koch CJ
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1024-31. PubMed ID: 17967299
[TBL] [Abstract][Full Text] [Related]
39. Hypoxia and differentiation in squamous cell carcinomas of the uterine cervix: pimonidazole and involucrin.
Azuma Y; Chou SC; Lininger RA; Murphy BJ; Varia MA; Raleigh JA
Clin Cancer Res; 2003 Oct; 9(13):4944-52. PubMed ID: 14581369
[TBL] [Abstract][Full Text] [Related]
40. Hypoxic changes in the central nervous system of noise-exposed mice.
Kim YJ; Kang HH; Ahn JH; Chung JW
Acta Otolaryngol Suppl; 2007 Oct; (558):73-7. PubMed ID: 17882574
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
